AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

(Sharecast News) - London equities slipped on Wednesday as stronger-than-expected UK inflation data offset a decline in US producer inflation, prompting investor caution over the interest rate outlook ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...